New data suggest that, among patients with first primary cutaneous melanoma, White patients have the highest absolute risk of second primary melanoma. However, Black and Asian or Pacific Islander patients have the highest relative risk of second primary melanoma when compared to the general population. These data were published in JAMA Dermatology.
Health Professionals
RELATIVITY-047 vs CheckMate 067 Matched Cohorts in Melanoma Show Similar Efficacy
During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the indirect comparison of ipilimumab plus nivolumab and nivolumab/relatlimab in advanced melanoma in the second article of a 2-part series.
Survival Outcomes in Melanoma May Be Improved by Statin Use (
Statin use may have beneficial effects on overall survival (OS) and
disease-free survival (DFS) among patients with melanoma, according
to results of a systematic review and meta-analysis published in
Melanoma Research.
IMA203 Displays Efficacy in Heavily Pretreated Melanoma
IMA203, a TCR-T agent targeting PRAME, was active and offered meaningful
progression-free survival (PFS) and overall survival (OS) outcomes in patients
with heavily pretreated melanoma, according to updated data from a phase 1b
study (NCT03686124) provided by Immatics NV.